121.89
0.68%
+0.82
After Hours:
121.92
0.03
+0.02%
Moderna Inc stock is currently priced at $121.89, with a 24-hour trading volume of 2.48M.
It has seen a +0.68% increased in the last 24 hours and a +15.93% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $121.1 pivot point. If it approaches the $123.5 resistance level, significant changes may occur.
Previous Close:
$121.07
Open:
$120
24h Volume:
2.48M
Market Cap:
$46.71B
Revenue:
$5.08B
Net Income/Loss:
$-5.97B
P/E Ratio:
-13.04
EPS:
-9.35
Net Cash Flow:
$-3.67B
1W Performance:
+9.36%
1M Performance:
+15.93%
6M Performance:
+70.86%
1Y Performance:
-7.48%
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
617-714-6500
Address
200 Technology Square, Cambridge
Moderna Inc Stock (MRNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-29-23 | Initiated | Canaccord Genuity | Hold |
Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
Jul-24-23 | Initiated | William Blair | Mkt Perform |
Jul-14-23 | Initiated | HSBC Securities | Reduce |
Jun-26-23 | Upgrade | UBS | Neutral → Buy |
Apr-26-23 | Initiated | Guggenheim | Neutral |
Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-21-22 | Initiated | UBS | Neutral |
Dec-07-21 | Initiated | Cowen | Market Perform |
Nov-09-21 | Initiated | Wolfe Research | Outperform |
Oct-22-21 | Initiated | Deutsche Bank | Sell |
Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-15-21 | Reiterated | Jefferies | Hold |
Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-09-20 | Downgrade | Needham | Buy → Hold |
Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-13-20 | Initiated | Jefferies | Buy |
Jun-30-20 | Initiated | Argus | Buy |
Jun-08-20 | Initiated | Barclays | Overweight |
Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Dec-03-19 | Resumed | BofA/Merrill | Buy |
Oct-25-19 | Initiated | ROTH Capital | Buy |
Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Navigating 6 Analyst Ratings For Moderna
Benzinga
Why Moderna Stock Blasted 13% Higher Today
The Motley Fool
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
Benzinga
Moderna (MRNA) Q1 2024 Earnings Call Transcript
The Motley Fool
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks Investment Research
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Moderna Inc Stock (MRNA) Financials Data
Moderna Inc (MRNA) Revenue 2024
MRNA reported a revenue (TTM) of $5.08 billion for the quarter ending March 31, 2024, a -65.59% decline year-over-year.
Moderna Inc (MRNA) Net Income 2024
MRNA net income (TTM) was -$5.97 billion for the quarter ending March 31, 2024, a -224.75% decrease year-over-year.
Moderna Inc (MRNA) Cash Flow 2024
MRNA recorded a free cash flow (TTM) of -$3.67 billion for the quarter ending March 31, 2024, a -700.00% decrease year-over-year.
Moderna Inc (MRNA) Earnings per Share 2024
MRNA earnings per share (TTM) was -$15.67 for the quarter ending March 31, 2024, a -235.44% decline year-over-year.
Moderna Inc Stock (MRNA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
AFEYAN NOUBAR | Director |
May 01 '24 |
Sale |
110.92 |
15,000 |
1,663,855 |
2,026,931 |
AFEYAN NOUBAR | Director |
Apr 24 '24 |
Sale |
108.32 |
15,000 |
1,624,836 |
2,041,931 |
AFEYAN NOUBAR | Director |
Apr 17 '24 |
Sale |
103.38 |
15,000 |
1,550,703 |
2,056,931 |
Hoge Stephen | President |
Apr 15 '24 |
Sale |
105.02 |
15,000 |
1,575,300 |
1,486,241 |
AFEYAN NOUBAR | Director |
Apr 10 '24 |
Sale |
107.12 |
15,000 |
1,606,865 |
2,071,931 |
Mock James M | Chief Financial Officer |
Apr 08 '24 |
Sale |
101.93 |
705 |
71,859 |
5,048 |
AFEYAN NOUBAR | Director |
Apr 03 '24 |
Sale |
101.68 |
15,000 |
1,525,268 |
2,086,931 |
AFEYAN NOUBAR | Director |
Mar 27 '24 |
Sale |
109.06 |
15,000 |
1,635,864 |
2,101,931 |
AFEYAN NOUBAR | Director |
Mar 20 '24 |
Sale |
102.39 |
15,000 |
1,535,820 |
2,116,931 |
Hoge Stephen | President |
Mar 15 '24 |
Sale |
103.17 |
15,000 |
1,547,550 |
1,501,241 |
About Moderna Inc
Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):